Latham & Watkins Advises Frequency Therapeutics in Merger With Korro Bio

Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. (Nasdaq: FREQ) have announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to operate under Korro Bio, Inc. and will apply to trade on Nasdaq under the ticker symbol “KRRO”.

Latham & Watkins LLP represents Frequency Therapeutics in the transaction with a M&A and capital markets deal team led by Chicago partner Bradley Faris and Boston partners Jennifer Yoon and John Chory, with associates Henna Jalal, Brian Baloun, Nicole Fu, Gen Crescenzo, and Jihoo Kim. Advice was also provided on tax matters by New York partner Jocelyn Noll, with associate Jeremiah Cowen; on benefits and compensation matters by Washington, D.C. partner Matthew Conway, with associates Ashlie Lawton and Dane Rebkowec; on intellectual property matters by Bay Area partner Christopher Hazuka, with associate Arun Mohan; on data privacy matters by Bay Area partner Heather Deixler, with associate Heather Lui; on healthcare regulatory matters by Bay Area partner Betty Pang, Washington, D.C. partner Elizabeth Richards, and Paris/Brussels partner Eveline Van Keymeulen, with associates Nathan Beaton, Kathryn Culver, Jeanne Fabre, and Alexandra Lauré; and on HSR matters by Washington, D.C. counsel Patrick English.